Ziihera® plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
U.S. FDA Approves Ziihera® with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
Jazz Pharmaceuticals Provides Update on Zepzelca® Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Angkor Resources Presents Its Proposed 2027 Work Program For Block Viii To The Cambodian Government At The Joint Review Committee
Blue Jay Gold Announces Materials Purchase Agreement With Ocean Partners for Remediation Material at Steller
